CD274 and neoplasm: Another clinical trial, KEYNOTE-028, defined PD-L1 positivity as \documentclass[12pt]{minimal}\usepackage{amsmath}\usepackage{wasysym}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{amsbsy}\usepackage{mathrsfs}\usepackage{upgreek}\setlength{\oddsidemargin}{-69pt}\begin{document}$$\ge 1{\text{\% }}$$\end{document}≥1\% PD-L1-positive cells (including tumor cells, lymphocytes and macrophages), enrolled advanced solid tumors, and confirmed that the expression of PD-L1 was associated with clinical efficacy and predicted the response to pembrolizumab [27].